Codexis Stock Price, News & Analysis (NASDAQ:CDXS)

$9.35 +0.55 (+6.25 %)
(As of 02/19/2018 05:00 AM ET)
Previous Close$8.80
Today's Range$8.85 - $9.40
52-Week Range$3.60 - $9.45
Volume290,600 shs
Average Volume253,924 shs
Market Capitalization$452.04 million
P/E Ratio-14.38
Dividend YieldN/A
Beta-1.61

About Codexis (NASDAQ:CDXS)

Codexis logoCodexis, Inc. is a developer of biocatalysts for the pharmaceutical and fine chemicals markets. The Company's CodeEvolver protein engineering technology platform, which introduces genetic mutations into genes in order to give rise to changes in the enzymes that they produce, overcomes many of the limitations, allowing customers to evolve and optimize biocatalysts to perform specific and desired chemical reactions at commercial scale. The Company's pharmaceutical products include enzymes, pharmaceutical intermediates, active pharmaceutical ingredients (APIs) and Codex Biocatalyst Panels and Kits. The fine chemicals market consists of several market verticals, including food and food ingredients, animal feed, flavors and fragrances, and agricultural chemicals. The Company also uses its technology to develop an early stage, enzyme therapeutic product candidate for the treatment of phenylketonuria (PKU) in humans through oral administration.

Receive CDXS News and Ratings via Email

Sign-up to receive the latest news and ratings for CDXS and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biotechnology & Medical Research
Sub-IndustryBiotechnology
SectorHealthcare
SymbolNASDAQ:CDXS
CUSIP19200510
Phone+1-650-4218100

Debt

Debt-to-Equity RatioN/A
Current Ratio2.05%
Quick Ratio2.00%

Price-To-Earnings

Trailing P/E Ratio-14.3846153846154
Forward P/E Ratio-20.33
P/E GrowthN/A

Sales & Book Value

Annual Sales$48.84 million
Price / Sales9.26
Cash FlowN/A
Price / CashN/A
Book Value$0.46 per share
Price / Book20.33

Profitability

Trailing EPS($0.65)
Net Income$-8,550,000.00
Net Margins-76.37%
Return on Equity-140.02%
Return on Assets-73.00%

Miscellaneous

Employees106
Outstanding Shares48,350,000

Codexis (NASDAQ:CDXS) Frequently Asked Questions

What is Codexis' stock symbol?

Codexis trades on the NASDAQ under the ticker symbol "CDXS."

How were Codexis' earnings last quarter?

Codexis, Inc. (NASDAQ:CDXS) announced its earnings results on Tuesday, August, 9th. The biotechnology company reported $0.12 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.03 by $0.09. The biotechnology company had revenue of $16 million for the quarter, compared to analyst estimates of $15.10 million. Codexis had a negative return on equity of 140.02% and a negative net margin of 76.37%. Codexis's revenue for the quarter was up 166.7% compared to the same quarter last year. During the same period in the previous year, the firm earned ($0.14) earnings per share. View Codexis' Earnings History.

When will Codexis make its next earnings announcement?

Codexis is scheduled to release their next quarterly earnings announcement on Wednesday, March, 7th 2018. View Earnings Estimates for Codexis.

Where is Codexis' stock going? Where will Codexis' stock price be in 2018?

2 brokers have issued 12-month target prices for Codexis' stock. Their predictions range from $8.50 to $11.00. On average, they expect Codexis' stock price to reach $9.75 in the next year. View Analyst Ratings for Codexis.

Who are some of Codexis' key competitors?

Who are Codexis' key executives?

Codexis' management team includes the folowing people:

  • Bernard J. Kelley, Chairman of the Board (Age 73)
  • John J. Nicols, President, Chief Executive Officer, Director (Age 51)
  • Gordon T. Sangster, Chief Financial Officer, Senior Vice President (Age 61)
  • Douglas T. Sheehy J.D., Executive Vice President, Chief Administrative Officer, General Counsel, Secretary (Age 50)
  • Michael Douglas Arthur Aldridge, Senior Vice President - Corporate & Strategic Development
  • James Lalonde, Senior Vice President, Research & Development (Age 54)
  • Thomas R. Baruch J.D., Chairman Emeritus
  • Pam P. Cheng, Director (Age 45)
  • Kathleen Sereda Glaub, Director
  • Patrick Y. Yang, Director (Age 69)

Who owns Codexis stock?

Codexis' stock is owned by many different of retail and institutional investors. Top institutional investors include Telemark Asset Management LLC (6.72%), BlackRock Inc. (5.53%), Prescott Group Capital Management L.L.C. (4.41%), William Blair Investment Management LLC (2.93%), Cortina Asset Management LLC (2.09%) and Wells Fargo & Company MN (2.07%). Company insiders that own Codexis stock include Bernard J Kelley, Dennis P Wolf, Patrick Y Yang, Ventures Fund Vii LP Vivo, Ventures Vii Affiliates F Vivo and Vivo Ventures Vii, Llc. View Institutional Ownership Trends for Codexis.

Who sold Codexis stock? Who is selling Codexis stock?

Codexis' stock was sold by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, William Blair Investment Management LLC, Cortina Asset Management LLC, Strs Ohio and Rhumbline Advisers. View Insider Buying and Selling for Codexis.

Who bought Codexis stock? Who is buying Codexis stock?

Codexis' stock was acquired by a variety of institutional investors in the last quarter, including Telemark Asset Management LLC, Wells Fargo & Company MN, EAM Investors LLC, Prescott Group Capital Management L.L.C., Essex Investment Management Co. LLC, Pratt Collard Advisory Partners LLC, Two Sigma Investments LP and Deutsche Bank AG. View Insider Buying and Selling for Codexis.

How do I buy Codexis stock?

Shares of Codexis can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Codexis' stock price today?

One share of Codexis stock can currently be purchased for approximately $9.35.

How big of a company is Codexis?

Codexis has a market capitalization of $452.04 million and generates $48.84 million in revenue each year. The biotechnology company earns $-8,550,000.00 in net income (profit) each year or ($0.65) on an earnings per share basis. Codexis employs 106 workers across the globe.

How can I contact Codexis?

Codexis' mailing address is 200 Penobscot Dr, REDWOOD CITY, CA 94063-4718, United States. The biotechnology company can be reached via phone at +1-650-4218100 or via email at [email protected]


MarketBeat Community Rating for Codexis (CDXS)

Community Ranking:  2.3 out of 5 (star star)
Outperform Votes:  144 (Vote Outperform)
Underperform Votes:  163 (Vote Underperform)
Total Votes:  307
MarketBeat's community ratings are surveys of what our community members think about Codexis and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Codexis (NASDAQ:CDXS) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.002.672.752.75
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $9.75$8.33$7.81$6.94
Price Target Upside: 66.67% upside42.45% upside33.55% upside29.67% upside

Codexis (NASDAQ:CDXS) Consensus Price Target History

Price Target History for Codexis (NASDAQ:CDXS)

Codexis (NASDAQ:CDXS) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
11/21/2017HC WainwrightReiterated RatingBuy$8.50N/AView Rating Details
10/13/2017Jefferies GroupBoost Price TargetBuy$9.00 -> $11.00N/AView Rating Details
1/26/2017First AnalysisDowngradeOverweight -> Equal Weight$5.50N/AView Rating Details
1/4/2017Ladenburg Thalmann Financial ServicesUpgradeNeutral -> Buy$6.25N/AView Rating Details
(Data available from 2/19/2016 forward)

Earnings

Codexis (NASDAQ:CDXS) Earnings History and Estimates Chart

Earnings by Quarter for Codexis (NASDAQ:CDXS)

Codexis (NASDAQ CDXS) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/7/2018$0.06N/AView Earnings Details
11/9/2017Q3 2017($0.16)($0.21)$10.00 million$9.98 millionViewN/AView Earnings Details
8/9/2017Q2 2017($0.13)($0.13)$9.61 million$10.30 millionViewListenView Earnings Details
5/9/2017Q1 2017($0.15)($0.18)$9.23 million$7.97 millionViewListenView Earnings Details
3/9/2017Q4 2016($0.11)($0.12)$9.15 million$10.00 millionViewListenView Earnings Details
11/8/2016Q3($0.14)$0.06$7.41 million$14.90 millionViewListenView Earnings Details
8/9/2016Q216$0.03$0.12$15.10 million$16.00 millionViewListenView Earnings Details
5/9/2016Q1($0.15)($0.11)$7.49 million$8.00 millionViewListenView Earnings Details
3/3/2016Q4($0.04)$0.02$11.63 million$11.60 millionViewN/AView Earnings Details
11/4/2015Q315($0.11)$0.13$8.85 million$17.40 millionViewListenView Earnings Details
8/11/2015Q215($0.14)($0.14)$7.34 million$6.02 millionViewListenView Earnings Details
5/7/2015Q115($0.12)($0.14)$8.00 million$6.80 millionViewListenView Earnings Details
3/3/2015Q414$0.01$0.07$13.30 million$14.20 millionViewListenView Earnings Details
11/4/2014Q314($0.06)($0.05)$9.00 million$7.47 millionViewListenView Earnings Details
8/6/2014Q214($0.15)($0.22)$8.50 million$6.60 millionViewListenView Earnings Details
5/7/2014Q114($0.10)($0.17)$10.00 million$7.10 millionViewListenView Earnings Details
3/11/2014Q413($0.21)($0.26)$10.00 million$9.50 millionViewListenView Earnings Details
11/12/2013Q313($0.31)($0.24)$8.50 million$3.90 millionViewListenView Earnings Details
8/9/2013Q2 2013($0.28)($0.33)$9.00 million$6.97 millionViewListenView Earnings Details
5/7/2013Q1 2013($0.36)($0.25)$7.63 million$11.48 millionViewListenView Earnings Details
2/27/2013Q4 2012($0.34)($0.41)$9.33 million$7.90 millionViewListenView Earnings Details
11/7/2012Q312($0.15)($0.06)$25.88 million$26.34 millionViewN/AView Earnings Details
8/9/2012($0.18)($0.15)ViewN/AView Earnings Details
5/10/2012($0.15)($0.21)ViewN/AView Earnings Details
2/7/2012($0.11)($0.15)ViewN/AView Earnings Details
11/1/2011($0.08)($0.08)ViewN/AView Earnings Details
7/28/2011($0.10)($0.14)ViewN/AView Earnings Details
5/5/2011($0.07)($0.10)ViewN/AView Earnings Details
2/3/2011($0.06)($0.01)ViewN/AView Earnings Details
10/28/2010Q3 2010($0.13)($0.08)ViewN/AView Earnings Details
8/5/2010Q2 2010($0.13)($0.15)ViewN/AView Earnings Details
5/26/2010Q1 2010($0.50)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

Codexis (NASDAQ:CDXS) Earnings Estimates

2018 EPS Consensus Estimate: ($0.13)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20181($0.13)($0.13)($0.13)
Q2 20181($0.13)($0.13)($0.13)
Q3 20181($0.07)($0.07)($0.07)
Q4 20181$0.20$0.20$0.20
(Earnings estimates data provided by Zacks Investment Research)

Dividends

Dividend History for Codexis (NASDAQ:CDXS)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Codexis (NASDAQ CDXS) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 9.80%
Institutional Ownership Percentage: 66.00%
Insider Trades by Quarter for Codexis (NASDAQ:CDXS)
Institutional Ownership by Quarter for Codexis (NASDAQ:CDXS)

Codexis (NASDAQ CDXS) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
9/14/2017Ventures Vii Affiliates F VivoMajor ShareholderSell1,060,000$5.78$6,126,800.00View SEC Filing  
8/21/2017Patrick Y YangDirectorBuy10,000$3.98$39,800.00348,234View SEC Filing  
11/15/2016Patrick Y YangDirectorBuy10,000$4.83$48,300.00320,340View SEC Filing  
9/8/2016Ventures Fund Vii L.P. VivoMajor ShareholderSell111,600$4.25$474,300.00View SEC Filing  
8/29/2016Dennis P WolfDirectorSell18,000$4.22$75,960.00132,360View SEC Filing  
8/24/2016Bernard J KelleyDirectorSell12,643$4.26$53,859.18234,906View SEC Filing  
8/16/2016Ventures Fund Vii L.P. VivoMajor ShareholderSell86,894$4.25$369,299.50View SEC Filing  
8/15/2016Vivo Ventures Vii, LlcMajor ShareholderSell50,000$4.27$213,500.00View SEC Filing  
8/4/2016Ventures Fund Vii L.P. VivoMajor ShareholderSell80,000$4.22$337,600.00View SEC Filing  
11/11/2015James LalondeSVPSell9,441$3.52$33,232.32168,011View SEC Filing  
9/11/2015Patrick Y YangDirectorBuy10,000$3.47$34,700.00290,246View SEC Filing  
9/10/2015Bernard J. KelleyDirectorSell5,200$3.45$17,940.00193,146View SEC Filing  
8/24/2015Patrick Y YangDirectorBuy10,000$3.84$38,400.00280,246View SEC Filing  
8/14/2015Patrick Y YangDirectorBuy20,000$3.97$79,400.00View SEC Filing  
6/15/2015Dennis P WolfDirectorSell35,416$4.10$145,205.60View SEC Filing  
11/18/2014Patrick Y YangDirectorBuy20,000$2.35$47,000.00View SEC Filing  
11/17/2014Patrick Y YangDirectorBuy20,000$2.34$46,800.00View SEC Filing  
8/12/2014Patrick Y YangDirectorBuy60,000$2.22$133,200.00View SEC Filing  
3/8/2013John J NicolsCEOBuy27,000$2.42$65,340.00View SEC Filing  
3/7/2013John J NicolsCEOBuy54,000$2.22$119,880.00View SEC Filing  
3/4/2013David D O'tooleCFOBuy10,000$2.02$20,200.00View SEC Filing  
11/12/2012David D O'tooleCFOBuy5,000$2.20$11,000.00View SEC Filing  
9/14/2012David D O'tooleCFOBuy5,000$2.78$13,900.00View SEC Filing  
9/14/2012Douglas T SheehySVPSell3,800$2.76$10,488.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Codexis (NASDAQ CDXS) News Headlines

Source:
DateHeadline
Codexis, Inc. (CDXS) Expected to Post Quarterly Sales of $22.96 MillionCodexis, Inc. (CDXS) Expected to Post Quarterly Sales of $22.96 Million
www.americanbankingnews.com - February 19 at 4:30 AM
Codexis (CDXS) Stock Rating Upgraded by Zacks Investment ResearchCodexis (CDXS) Stock Rating Upgraded by Zacks Investment Research
www.americanbankingnews.com - February 15 at 7:24 PM
Codexis Appoints Molecular Diagnostics Industry Veteran Shawn Clairmont to Lead High-Performance Enzymes CommercializationCodexis Appoints Molecular Diagnostics Industry Veteran Shawn Clairmont to Lead High-Performance Enzymes Commercialization
finance.yahoo.com - February 15 at 8:46 AM
Codexis to Present at the 25th International Molecular Medicine Tri-ConferenceCodexis to Present at the 25th International Molecular Medicine Tri-Conference
feeds.benzinga.com - February 12 at 7:43 AM
Zacks Investment Research Lowers Codexis (CDXS) to SellZacks Investment Research Lowers Codexis (CDXS) to Sell
www.americanbankingnews.com - February 9 at 7:16 PM
$22.96 Million in Sales Expected for Codexis, Inc. (CDXS) This Quarter$22.96 Million in Sales Expected for Codexis, Inc. (CDXS) This Quarter
www.americanbankingnews.com - February 2 at 4:42 AM
$0.05 EPS Expected for Codexis, Inc. (CDXS) This Quarter$0.05 EPS Expected for Codexis, Inc. (CDXS) This Quarter
www.americanbankingnews.com - January 31 at 1:20 PM
Commit To Purchase Codexis At $7.50, Earn 19.2% Annualized Using OptionsCommit To Purchase Codexis At $7.50, Earn 19.2% Annualized Using Options
www.nasdaq.com - January 24 at 4:45 PM
 Analysts Anticipate Codexis, Inc. (CDXS) Will Announce Quarterly Sales of $22.96 Million Analysts Anticipate Codexis, Inc. (CDXS) Will Announce Quarterly Sales of $22.96 Million
www.americanbankingnews.com - January 16 at 11:00 AM
 Brokerages Expect Codexis, Inc. (CDXS) to Announce $0.05 Earnings Per Share Brokerages Expect Codexis, Inc. (CDXS) to Announce $0.05 Earnings Per Share
www.americanbankingnews.com - January 14 at 1:40 PM
Codexis, Inc. (CDXS) Given Average Rating of "Hold" by AnalystsCodexis, Inc. (CDXS) Given Average Rating of "Hold" by Analysts
www.americanbankingnews.com - January 9 at 5:38 AM
Codexis (CDXS) versus Beyondspring (BYSI) Financial ContrastCodexis (CDXS) versus Beyondspring (BYSI) Financial Contrast
www.americanbankingnews.com - January 7 at 11:26 PM
ETFs with exposure to Codexis, Inc. : December 29, 2017ETFs with exposure to Codexis, Inc. : December 29, 2017
finance.yahoo.com - December 29 at 4:44 PM
 Brokerages Anticipate Codexis, Inc. (CDXS) to Announce $0.06 EPS Brokerages Anticipate Codexis, Inc. (CDXS) to Announce $0.06 EPS
www.americanbankingnews.com - December 28 at 7:30 PM
Codexis, Inc. :CDXS-US: Earnings Analysis: Q3, 2017 By the Numbers : December 28, 2017Codexis, Inc. :CDXS-US: Earnings Analysis: Q3, 2017 By the Numbers : December 28, 2017
finance.yahoo.com - December 28 at 4:35 PM
Codexis (CDXS) Upgraded to Buy at BidaskClubCodexis (CDXS) Upgraded to Buy at BidaskClub
www.americanbankingnews.com - December 16 at 2:52 PM
Codexis, Inc. (CDXS) Receives Average Rating of "Buy" from BrokeragesCodexis, Inc. (CDXS) Receives Average Rating of "Buy" from Brokerages
www.americanbankingnews.com - December 15 at 3:32 AM
$22.66 Million in Sales Expected for Codexis, Inc. (CDXS) This Quarter$22.66 Million in Sales Expected for Codexis, Inc. (CDXS) This Quarter
www.americanbankingnews.com - December 13 at 5:42 AM
Codexis, Inc. – Value Analysis (NASDAQ:CDXS) : December 12, 2017Codexis, Inc. – Value Analysis (NASDAQ:CDXS) : December 12, 2017
finance.yahoo.com - December 12 at 5:07 PM
Codexis, Inc. (CDXS) Expected to Post Earnings of $0.06 Per ShareCodexis, Inc. (CDXS) Expected to Post Earnings of $0.06 Per Share
www.americanbankingnews.com - December 11 at 1:34 PM
Codexis, Inc. breached its 50 day moving average in a Bullish Manner : CDXS-US : December 8, 2017Codexis, Inc. breached its 50 day moving average in a Bullish Manner : CDXS-US : December 8, 2017
finance.yahoo.com - December 8 at 10:05 AM
Codexis, Inc. (CDXS) Director Buys $39,800.00 in StockCodexis, Inc. (CDXS) Director Buys $39,800.00 in Stock
www.americanbankingnews.com - December 7 at 11:26 PM
Codexis (CDXS) Raised to "Hold" at BidaskClubCodexis (CDXS) Raised to "Hold" at BidaskClub
www.americanbankingnews.com - December 2 at 2:38 PM
ETFs with exposure to Codexis, Inc. : November 28, 2017ETFs with exposure to Codexis, Inc. : November 28, 2017
finance.yahoo.com - November 28 at 4:44 PM
Analyzing Galectin Therapeutics (GALT) and Codexis (CDXS)Analyzing Galectin Therapeutics (GALT) and Codexis (CDXS)
www.americanbankingnews.com - November 27 at 9:52 PM
Codexis, Inc. (CDXS) Rating Reiterated by HC WainwrightCodexis, Inc. (CDXS) Rating Reiterated by HC Wainwright
www.americanbankingnews.com - November 21 at 1:16 PM
Codexis, Inc. (CDXS) Given Consensus Rating of "Hold" by AnalystsCodexis, Inc. (CDXS) Given Consensus Rating of "Hold" by Analysts
www.americanbankingnews.com - November 20 at 3:58 AM
Codexis (CDXS) Presents At 8th Annual Craig-Hallum Alpha Select Conference - SlideshowCodexis (CDXS) Presents At 8th Annual Craig-Hallum Alpha Select Conference - Slideshow
seekingalpha.com - November 18 at 4:50 PM
Edited Transcript of CDXS earnings conference call or presentation 9-Nov-17 9:30pm GMTEdited Transcript of CDXS earnings conference call or presentation 9-Nov-17 9:30pm GMT
finance.yahoo.com - November 10 at 10:15 AM
Codexis to Present at Two Investment Conferences in NovemberCodexis to Present at Two Investment Conferences in November
finance.yahoo.com - November 9 at 7:52 PM
Codexis, Inc. to Host Earnings CallCodexis, Inc. to Host Earnings Call
finance.yahoo.com - November 9 at 7:52 PM
Codexis Reports Financial Results for the Third Quarter of 2017Codexis Reports Financial Results for the Third Quarter of 2017
finance.yahoo.com - November 9 at 7:52 PM
Codexis reports 3Q lossCodexis reports 3Q loss
finance.yahoo.com - November 9 at 7:52 PM
Codexis, Inc. breached its 50 day moving average in a Bullish Manner : CDXS-US : November 6, 2017Codexis, Inc. breached its 50 day moving average in a Bullish Manner : CDXS-US : November 6, 2017
finance.yahoo.com - November 6 at 6:14 PM
Codexis, Inc. (CDXS) Expected to Announce Earnings of -$0.16 Per ShareCodexis, Inc. (CDXS) Expected to Announce Earnings of -$0.16 Per Share
www.americanbankingnews.com - November 4 at 1:20 PM
ETFs with exposure to Codexis, Inc. : November 2, 2017ETFs with exposure to Codexis, Inc. : November 2, 2017
finance.yahoo.com - November 2 at 5:54 PM
Codexis to Hold 2017 Third Quarter Conference Call on November 9Codexis to Hold 2017 Third Quarter Conference Call on November 9
feeds.benzinga.com - November 2 at 7:43 AM
Codexis, Inc. (CDXS) Scheduled to Post Quarterly Earnings on MondayCodexis, Inc. (CDXS) Scheduled to Post Quarterly Earnings on Monday
www.americanbankingnews.com - October 30 at 8:50 AM
Codexis, Inc. (CDXS) Receives Consensus Rating of "Hold" from AnalystsCodexis, Inc. (CDXS) Receives Consensus Rating of "Hold" from Analysts
www.americanbankingnews.com - October 26 at 3:32 AM
1 Small-Cap Biotech Stock to Buy Right Now1 Small-Cap Biotech Stock to Buy Right Now
finance.yahoo.com - October 25 at 6:36 PM
ETFs with exposure to Codexis, Inc. : October 23, 2017ETFs with exposure to Codexis, Inc. : October 23, 2017
finance.yahoo.com - October 23 at 3:49 PM
Codexis, Inc. (CDXS) Expected to Announce Quarterly Sales of $10.00 MillionCodexis, Inc. (CDXS) Expected to Announce Quarterly Sales of $10.00 Million
www.americanbankingnews.com - October 17 at 2:02 AM
Analysts Issue Forecasts for Codexis, Inc.s Q4 2017 Earnings (CDXS)Analysts Issue Forecasts for Codexis, Inc.'s Q4 2017 Earnings (CDXS)
www.americanbankingnews.com - October 16 at 5:18 AM
Codexis, Inc. (CDXS) Price Target Raised to $11.00Codexis, Inc. (CDXS) Price Target Raised to $11.00
www.americanbankingnews.com - October 13 at 7:02 PM
Codexis Reaches Analyst Target PriceCodexis Reaches Analyst Target Price
www.thestreet.com - October 13 at 5:41 PM
HC Wainwright Boosts Codexis, Inc. (CDXS) Price Target to $8.50HC Wainwright Boosts Codexis, Inc. (CDXS) Price Target to $8.50
www.americanbankingnews.com - October 13 at 7:34 AM
Codexis And Nestle Health Science Enter Into Healthcare-Focused Protein Engineering Platform PartnershipCodexis And Nestle Health Science Enter Into Healthcare-Focused Protein Engineering Platform Partnership
www.thestreet.com - October 12 at 10:55 PM
Codexis and Nestlé Health Science Enter Into Healthcare-Focused Protein Engineering Platform PartnershipCodexis and Nestlé Health Science Enter Into Healthcare-Focused Protein Engineering Platform Partnership
finance.yahoo.com - October 12 at 5:53 PM
ETFs with exposure to Codexis, Inc. : October 12, 2017ETFs with exposure to Codexis, Inc. : October 12, 2017
finance.yahoo.com - October 12 at 5:53 PM
Codexis, Inc. :CDXS-US: Earnings Analysis: Q2, 2017 By the Numbers : October 11, 2017Codexis, Inc. :CDXS-US: Earnings Analysis: Q2, 2017 By the Numbers : October 11, 2017
finance.yahoo.com - October 11 at 6:34 PM

SEC Filings

Codexis (NASDAQ:CDXS) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Codexis (NASDAQ:CDXS) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Codexis (NASDAQ CDXS) Stock Chart for Monday, February, 19, 2018

Loading chart…

This page was last updated on 2/19/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.